Eternal founder Deepinder Goyal has responded to criticism surrounding Temple, the AI-powered wearable developed by his startup. Addressing concerns over its high price, scientific claims and intended use, Goyal said the product is designed for global markets and is not specifically targeted at India.
In a series of posts on X, Goyal said the company expects India to account for no more than 1% of Temple sales. He explained that the pricing reflects the work involved in developing the device and encouraged potential buyers to wait for user reviews if they remain unsure about its value.
Goyal also said the company does not want people to support Temple simply because it is an Indian startup. He stressed that the aim is to compete globally and build support through innovation.
Temple Is a Fitness and AI Device, Says Goyal
Responding to questions about the device’s scientific basis, Goyal said Temple is strictly a fitness and AI product and does not make medical claims. He clarified that the device has not been proven to diagnose or prevent diseases and is not intended to replace medical consultations.
He also addressed questions surrounding Brain Flow, a feature that has attracted attention since the product’s announcement. Goyal said Brain Flow is not the device’s primary focus. Instead, he identified Entropy as the central concept behind Temple and said the company plans to share more information about it.
Company to Explain Brain Flow Technology
Goyal said the company would publish a detailed note explaining how Brain Flow is calculated, its potential applications and its limitations. He added that Temple would obtain regulatory clearances wherever required before making claims that need such approvals.
The response follows criticism from social media users and members of the medical community over the wearable’s pricing and claims related to brain monitoring. Goyal said consumers are free to wait for stronger, peer-reviewed scientific evidence before deciding whether to purchase the device.
